MetaCap

China Pharma (CPHI) vs TransCode Therapeutics (RNAZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

China Pharma (CPHI) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 72.6% versus a loss of 86.6%. Over five years, CPHI leads with a -99.8% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($20.1 million vs $18.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CPHI-72.60%RNAZ-86.57%
+431%+160%-111%
Nov 21, 20251 yearNov 20, 2026
CPHI-99.85%RNAZ-100.00%
+17%-45%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CPHI versus RNAZ key metrics
MetricCPHIRNAZ
Share price$0.4384$1.16
Market cap$18.86M$20.07M
1-day change-13.00%-10.77%
YTD return-63.77%-83.02%
1-year return-72.60%-86.57%
5-year return-99.84%-100.00%
EPS (TTM)$-0.42$-47.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.14M—
Revenue growth (YoY)-8.49%—
Net income (latest FY)$-3.19M$-34.66M
Gross margin-3.18%—
Operating margin-78.16%—
Net margin-76.91%—
52-week high$19.19$12.60
52-week low$0.38$1.01
Distance from 52-week high-97.72%-90.79%
Average volume1.60M52.03K
Shares outstanding43.02M17.30M
Employees21512
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CPHI has outperformed RNAZ by 14.0 percentage points over the past year.

About China Pharma

CPHI stock →

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.

Health Care · Biotechnology: Pharmaceutical Preparations · 215 employees

About TransCode Therapeutics

RNAZ stock →

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

CPHI vs RNAZ FAQ

Which is bigger, China Pharma or TransCode Therapeutics?

TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $20.07M compared with $18.86M for China Pharma (CPHI).

Which stock has performed better over the past year, CPHI or RNAZ?

CPHI returned -72.60% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.

Are China Pharma and TransCode Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons